Cyclodipeptides show potential as therapeutic agents in oxidative damage-related diseases by modulating oxidative stress pathways, protecting neurons, and providing heart-protective effects.
Do cyclodipeptides mitigate oxidative damage in chronic diseases?
Cyclodipeptides show broad therapeutic potential as antioxidant agents across multiple chronic disease models, including cardiovascular, neurological, and respiratory conditions.
Oxidative stress results from an imbalance between free radicals—such as reactive oxygen species (ROS) and reactive nitrogen species (RNS)—and the body’s antioxidant defenses. This imbalance contributes to the progression of diseases affecting the nervous, cardiovascular, and respiratory systems. Cyclodipeptides (CDPs) have exhibited significant antioxidant, cytoprotective, and neuroprotective properties, making them promising candidates for mitigating oxidative damage. Their ability to modulate oxidative stress pathways highlights their potential as therapeutic agents in oxidative damage-related diseases. This review discusses the role of free radicals in oxidative stress before exploring the importance of different types of CDPs in counteracting oxidative damage in various diseases. • CDPs regulate oxidative stress pathways to reduce cell damage. • CDPs cross the blood-brain barrier and protect neurons in Alzheimer’s and Parkinson’s. • CDPs trigger apoptosis and overcome drug resistance in multiple cancer cell types. • CDPs modulate cardiac ion channels, providing anti-arrhythmic and heart-protective effects. • CDPs suppress viral replication and lung inflammation in respiratory disease models.
Rajan et al. (Sat,) conducted a review in Oxidative damage-related chronic diseases. Cyclodipeptides (CDPs) was evaluated. Cyclodipeptides show potential as therapeutic agents in oxidative damage-related diseases by modulating oxidative stress pathways, protecting neurons, and providing heart-protective effects.